Skip to main content
OTCMKTS:SGIOY

Shionogi & Co., Ltd. News Headlines

$13.19
+0.10 (+0.76 %)
(As of 05/14/2021 03:55 PM ET)
Add
Compare
Today's Range
$12.99
$13.43
50-Day Range
$12.76
$13.89
52-Week Range
$11.49
$16.89
Volume166,561 shs
Average Volume162,104 shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A

Headlines

Shionogi & Co., Ltd. (OTCMKTS SGIOY) News Headlines Today

SourceHeadline
Japans Shionogi may roll out COVID vaccines this year -KyodoJapan's Shionogi may roll out COVID vaccines this year -Kyodo
cn.reuters.com - May 11 at 10:23 AM
Japans Shionogi may roll out COVID vaccines this year: KyodoJapan's Shionogi may roll out COVID vaccines this year: Kyodo
reuters.com - May 10 at 9:59 AM
GSKs ViiV says HIV drug gets rolling probe from US watchdogGSK's ViiV says HIV drug gets rolling probe from US watchdog
lse.co.uk - May 4 at 9:51 AM
Shionogi Strengthens U.S. Executive Leadership Team to Support GrowthShionogi Strengthens U.S. Executive Leadership Team to Support Growth
businesswire.com - May 3 at 5:39 PM
Shionogi & Co., Ltd. (OTCMKTS:SGIOY) Short Interest Down 46.2% in AprilShionogi & Co., Ltd. (OTCMKTS:SGIOY) Short Interest Down 46.2% in April
americanbankingnews.com - April 30 at 6:18 PM
Antibiotics Market Research Report by Action Mechanism, by Drug Class, by Spectrum - Global Forecast to 2025 - Cumulative Impact of COVID-19Antibiotics Market Research Report by Action Mechanism, by Drug Class, by Spectrum - Global Forecast to 2025 - Cumulative Impact of COVID-19
ca.finance.yahoo.com - April 21 at 9:34 AM
Antibacterial Drugs Market Analysis, Impact of COVID-19 , Revenues and Regional Outlook | Forecast to 2027Antibacterial Drugs Market Analysis, Impact of COVID-19 , Revenues and Regional Outlook | Forecast to 2027
marketwatch.com - April 20 at 7:26 AM
Antibacterial Market Research Report by Crop, by Type, by Application - Global Forecast to 2025 - Cumulative Impact of COVID-19Antibacterial Market Research Report by Crop, by Type, by Application - Global Forecast to 2025 - Cumulative Impact of COVID-19
ca.finance.yahoo.com - April 19 at 10:34 AM
Antibiotics Market Research Report by Drug Class, by Action Mechanism - Global Forecast to 2025 - Cumulative Impact of COVID-19Antibiotics Market Research Report by Drug Class, by Action Mechanism - Global Forecast to 2025 - Cumulative Impact of COVID-19
finance.yahoo.com - March 30 at 3:17 PM
Prescription Drugs Market Value Forecasted To Reach US$ 1,567.2 Billion By 2027: Acumen Research And ConsultingPrescription Drugs Market Value Forecasted To Reach US$ 1,567.2 Billion By 2027: Acumen Research And Consulting
finance.yahoo.com - March 30 at 3:17 PM
Cefzon Market Size, Growth Share & Trends Analysis, Technological Advancements, Latest Research by Regions with COVID-19 Impact Forecast to 2025Cefzon Market Size, Growth Share & Trends Analysis, Technological Advancements, Latest Research by Regions with COVID-19 Impact Forecast to 2025
marketwatch.com - March 19 at 6:15 AM
China Mobile Considers A-Share Listing After U.S. RemovalChina Mobile Considers A-Share Listing After U.S. Removal
ca.finance.yahoo.com - March 17 at 9:34 AM
Duloxetine API is expected to grow at a CAGR of around 4.1% from 2020 to 2027 | ARCDuloxetine API is expected to grow at a CAGR of around 4.1% from 2020 to 2027 | ARC
marketwatch.com - March 10 at 5:42 AM
Anti-aging biotechs first clinical trial aims to breathe new life into old bloodAnti-aging biotech's first clinical trial aims to breathe new life into old blood
bizjournals.com - February 25 at 1:29 PM
Sage Therapeutics Announces Fourth Quarter and Full Year 2020 Financial Results and Highlights Pipeline and Business ProgressSage Therapeutics Announces Fourth Quarter and Full Year 2020 Financial Results and Highlights Pipeline and Business Progress
uk.finance.yahoo.com - February 24 at 7:26 AM
Transforming Growth Factor Beta 1 Market Healthcare, Clinical Reviews, Survey Reports 2021Transforming Growth Factor Beta 1 Market Healthcare, Clinical Reviews, Survey Reports 2021
marketwatch.com - February 20 at 7:34 AM
Duloxetine API Market 2021 Growth, Segments, by Size, Share, Key News and Top Companies Overview to 2023Duloxetine API Market 2021 Growth, Segments, by Size, Share, Key News and Top Companies Overview to 2023
marketwatch.com - February 16 at 10:30 PM
Global Opioid Induced Constipation Drugs Market 2020 by Key Players, Segmentation, Industry Growth, Opportunities and Forecast by 2025Global Opioid Induced Constipation Drugs Market 2020 by Key Players, Segmentation, Industry Growth, Opportunities and Forecast by 2025
marketwatch.com - February 9 at 1:00 PM
TOP NEWS: GlaxoSmithKline Notes EU Approval For HIV Drug RukobiaTOP NEWS: GlaxoSmithKline Notes EU Approval For HIV Drug Rukobia
lse.co.uk - February 8 at 9:51 AM
Global Antidepressant Drugs Market 2021 Analysis by Size & Share, Future Demands, Trends Evaluation, Business Growth Strategies and Forecast to 2024Global Antidepressant Drugs Market 2021 Analysis by Size & Share, Future Demands, Trends Evaluation, Business Growth Strategies and Forecast to 2024
marketwatch.com - February 4 at 9:49 AM
Shionogi & Co., Ltd. (4507.T)Shionogi & Co., Ltd. (4507.T)
finance.yahoo.com - February 1 at 6:46 PM
What Wall Street expects from Shionogis earningsWhat Wall Street expects from Shionogi's earnings
markets.businessinsider.com - January 30 at 1:38 PM
Japans Shionogi sells coronavirus drug rights to U.S. biotech BioAgeJapan's Shionogi sells coronavirus drug rights to U.S. biotech BioAge
reuters.com - January 26 at 6:18 PM
UPDATE 1-Japans Shionogi sells coronavirus drug rights to U.S. biotech BioAgeUPDATE 1-Japan's Shionogi sells coronavirus drug rights to U.S. biotech BioAge
reuters.com - January 26 at 8:18 AM
GSK Jan 2021 35.500 putGSK Jan 2021 35.500 put
ca.finance.yahoo.com - January 23 at 5:53 PM
TOP NEWS: Glaxo, Johnson & Johnson Long-Acting HIV Drug Approved In USTOP NEWS: Glaxo, Johnson & Johnson Long-Acting HIV Drug Approved In US
lse.co.uk - January 22 at 9:29 AM
Shionogi & Co LtdShionogi & Co Ltd
cnbc.com - January 16 at 10:13 PM
Glaxo, Pfizers ViiV Gets EU Approval For Tivicay In Children With HIVGlaxo, Pfizer's ViiV Gets EU Approval For Tivicay In Children With HIV
lse.co.uk - January 13 at 7:23 AM
Roches Xofluza approved by the European Commission for the treatment of influenza, the first new influenza antiviral for patients in almost 20 yearsRoche's Xofluza approved by the European Commission for the treatment of influenza, the first new influenza antiviral for patients in almost 20 years
benzinga.com - January 11 at 7:25 AM
Factbox-When and which COVID-19 vaccines are likely to be available in AsiaFactbox-When and which COVID-19 vaccines are likely to be available in Asia
msn.com - January 7 at 1:44 AM
Influenza Medication Market Global Trends, Market Share, Industry Size, Growth, Opportunities and Market Forecast 2020 to 2027Influenza Medication Market Global Trends, Market Share, Industry Size, Growth, Opportunities and Market Forecast 2020 to 2027
marketwatch.com - December 20 at 2:51 PM
Covid-19: Know the vaccine plans of India, Philippines and othersCovid-19: Know the vaccine plans of India, Philippines and others
msn.com - December 11 at 3:17 AM
Antidepressants Drugs Market Size 2021 to 2025 Capacity, Production and Consumption Professional Analysis and Impact of COVID-19Antidepressants Drugs Market Size 2021 to 2025 Capacity, Production and Consumption Professional Analysis and Impact of COVID-19
marketwatch.com - December 8 at 5:33 PM
Cefzon Market Outlook 2026: Top Companies, Trends and Growth Factors Details for Business DevelopmentCefzon Market Outlook 2026: Top Companies, Trends and Growth Factors Details for Business Development
marketwatch.com - December 4 at 3:00 AM
Coronavirus: When and which Covid-19 vaccines are likely to be available in AsiaCoronavirus: When and which Covid-19 vaccines are likely to be available in Asia
msn.com - November 26 at 12:28 PM
Factbox: When and which COVID-19 vaccines are likely to be available in AsiaFactbox: When and which COVID-19 vaccines are likely to be available in Asia
msn.com - November 26 at 7:28 AM
F. Hoffmann-La Roche Ltd: CHMP recommends EU approval of Roches Xofluza (baloxavir marboxil) for the treatment of influenzaF. Hoffmann-La Roche Ltd: CHMP recommends EU approval of Roche's Xofluza (baloxavir marboxil) for the treatment of influenza
finanznachrichten.de - November 15 at 11:10 PM
CHMP recommends EU approval of Roches Xofluza(R) (baloxavir marboxil) for the treatment of influenzaCHMP recommends EU approval of Roche's Xofluza(R) (baloxavir marboxil) for the treatment of influenza
marketwatch.com - November 14 at 2:18 PM
Glaxo, Pfizers HIV Tablet Treatment Gets Positive Opinion In EUGlaxo, Pfizer's HIV Tablet Treatment Gets Positive Opinion In EU
lse.co.uk - November 13 at 10:07 AM
REFILE-Japan's Shionogi readies COVID-19 vaccine for December trial- CEOREFILE-Japan's Shionogi readies COVID-19 vaccine for December trial- CEO
finance.yahoo.com - October 29 at 9:24 AM
Shionogi Announces Publication of a New Systematic Review in CHEST Highlighting the Importance of Early, Appropriate Therapy to Improve Meaningful Outcomes Like Mortality in ...Shionogi Announces Publication of a New Systematic Review in CHEST Highlighting the Importance of Early, Appropriate Therapy to Improve Meaningful Outcomes Like Mortality in ...
businesswire.com - October 1 at 1:33 PM
Japan’s Shionogi to Launch 25-Minute Coronavirus Test Next MonthJapan’s Shionogi to Launch 25-Minute Coronavirus Test Next Month
msn.com - August 8 at 5:28 AM
Ping An concretiza parceria com farmacêutica Shionogi para servir 315 milhões de clientesPing An concretiza parceria com farmacêutica Shionogi para servir 315 milhões de clientes
msn.com - August 4 at 7:40 PM
Shionogi & Co., Ltd. 2020 Q1 - Results - Earnings Call PresentationShionogi & Co., Ltd. 2020 Q1 - Results - Earnings Call Presentation
seekingalpha.com - July 31 at 12:28 AM
Ping An and Shionogi launches joint venturesPing An and Shionogi launches joint ventures
seekingalpha.com - July 27 at 2:32 PM
Japans Shionogi targets annual vaccine output of 30 millionJapan's Shionogi targets annual vaccine output of 30 million
www.nasdaq.com - July 20 at 12:36 PM
A Speculative Stock That Makes Sense in JapanA Speculative Stock That Makes Sense in Japan
realmoney.thestreet.com - June 22 at 8:18 AM
Japans Shionogi partners with universities to develop visual coronavirus testJapan's Shionogi partners with universities to develop visual coronavirus test
uk.reuters.com - June 22 at 12:26 AM
Shionogi boss cautions against hopes of early coronavirus vaccineShionogi boss cautions against hopes of early coronavirus vaccine
www.ft.com - June 14 at 7:48 AM
Japans AnGes speeds towards 2021 rollout in coronavirus vaccine warJapan's AnGes speeds towards 2021 rollout in coronavirus 'vaccine war'
finance.yahoo.com - June 10 at 6:18 AM
This page was last updated on 5/16/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.